查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1607982

止血诊断市场：按产品类型、测试类型、最终用途划分 - 2025-2030 年全球预测

Hemostasis Diagnostics Market by Product (Consumables, Laboratory Analyzers, Point-of-Care Testing Systems), Test Type (Activated Clotting Time, Activated Partial Thromboplastin Time, D Dimer Test), End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年止血诊断市值为5.7932亿美元，预计到2024年将达到6.201亿美元，复合年增长率为8.04%，到2030年将达到9.9577亿美元。

止血诊断市场的范围包括旨在识别和管理止血疾病的产品和服务，例如血块形成、血小板功能和凝血因子的测试。作为医疗保健系统的关键组成部分，这些诊断对于诊断血友病、血栓症和其他出血性疾病等疾病至关重要。应用范围包括医院、诊断中心、研究机构和学术机构，最终用途范围从个别患者诊断到大规模筛检计画。市场成长受到血液相关疾病日益流行、就地检验等技术进步以及易患此类疾病的老年人口增加的影响。开发和部署新的诊断技术（例如基于人工智慧的资料分析和个人化医疗方法）存在商机，以提高诊断的速度和准确性。公司应该探索与生物技术公司和医疗保健提供者的合作伙伴关係，以利用这些进步。然而，与诊断工具相关的高成本和复杂的监管要求等挑战可能会阻碍市场扩张。发展中地区的能见度有限和基础设施不足进一步凸显了潜在的成长障碍。为了最大限度地发挥成长潜力，公司应该专注于创新，例如提高现有测试的灵敏度和特异性或设计可提供快速可靠结果的携带式诊断设备。与学术机构合作进行前沿研究以及利用巨量资料来提高诊断准确性是利用这些机会的基本策略。竞争的市场格局是动态的，需要适应性策略来应对监管环境和技术转变，因此保持竞争优势并满足不断变化的医疗保健需求需要采取积极主动的方法。

主要市场统计
基准年[2023] 57932万美元
预计年份 [2024] 6.201 亿美元
预测年份 [2030] 9.9577 亿美元
复合年增长率（%） 8.04%

市场动态：快速发展的止血诊断市场的关键市场洞察

供需的动态交互作用正在改变止血诊断市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球止血疾病增加
    • 倾向于就地检验解决方案
    • 提高对止血疾病的认识并重视早期诊断
  • 市场限制因素
    • 诊断成本上升和产品召回
  • 市场机会
    • 透过个人化医疗实现个人化治疗
    • 止血诊断方法的进展
  • 市场挑战
    • 止血诊断的复杂测试方法

波特五力：开拓止血诊断市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对止血诊断市场的影响

外部宏观环境因素在塑造止血诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解止血诊断市场的竞争状况

对止血诊断市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵止血诊断市场厂商绩效评估

FPNV定位矩阵是评估止血诊断市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘止血诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，止血诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球止血疾病的发生率增加
      • 就地检验解决方案的趋势
      • 提高对止血疾病的认识以及早期诊断的重要性
    • 抑制因素
      • 高诊断成本和产品召回率
    • 机会
      • 利用个人化医疗方法为患者提供量身订製的治疗
      • 止血诊断方法的进展
    • 任务
      • 止血诊断的复杂测试方法
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章止血诊断市场：副产品

  • 消耗品
  • 实验室分析仪
  • 就地检验系统

第七章按测试类型分類的止血诊断市场

  • 活化凝血时间
  • 活化部份凝血活酵素时间
  • D-二聚体测试
  • 纤维蛋白原测试
  • 血小板凝集试验
  • 凝血酶原时间（PT）测试

第八章止血诊断市场：依最终用途

  • 居家照护环境
  • 医院/诊所
  • 独立诊断实验室

第九章 北美、南美止血诊断药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太止血诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章：欧洲、中东和非洲止血诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • ARUP Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaPharma Group, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Grifols, SA
  • Haemonetics Corporation
  • Helena Laboratories Corporation
  • HemoSonics, LLC
  • HORIBA Group
  • Laboratory Corporation of America Holdings
  • Medtronic PLC
  • Merck & Co., Inc.
  • Randox Laboratories Ltd.
  • Siemens AG
  • Stago Group
  • Sysmex America, Inc.
  • Sysmex Europe SE
  • Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH
  • Thermo Fisher Scientific Inc.
  • Werfen, SA
Product Code: MRR-DD0700E81E58

The Hemostasis Diagnostics Market was valued at USD 579.32 million in 2023, expected to reach USD 620.10 million in 2024, and is projected to grow at a CAGR of 8.04%, to USD 995.77 million by 2030.

The scope of the hemostasis diagnostics market encompasses products and services aimed at identifying and managing hemostatic disorders, including tests for blood clot formation, platelet function, and coagulation factors. As critical components of the healthcare system, these diagnostics are vital for diagnosing conditions such as hemophilia, thrombosis, and other bleeding disorders. Their applications extend across hospitals, diagnostic centers, research institutions, and academic settings, with an end-use scope that includes individual patient diagnostics and large-scale screening programs. Market growth is influenced by an increasing prevalence of blood-related disorders, advancements in technology like point-of-care testing, and a growing geriatric population susceptible to such conditions. Opportunities exist in the development and deployment of novel diagnostic technologies, such as AI-driven data analysis and personalized medicine approaches, to enhance diagnostic speed and accuracy. Businesses should explore collaborations with biotechnology firms and healthcare providers to leverage these advancements. However, challenges including high costs associated with diagnostic tools and complex regulatory requirements can impede market expansion. Limitations in awareness and inadequate infrastructure in developing regions further stress potential growth barriers. To maximize growth potential, companies could focus on innovations like improving the sensitivity and specificity of existing tests, or devising portable diagnostic devices that offer rapid, reliable results. Collaboration with academic institutions for cutting-edge research and leveraging big data to refine diagnostic precision are vital strategies for capitalizing on these opportunities. The nature of the hemostasis diagnostics market is dynamic and requires adaptive strategies to navigate regulatory landscapes and technological shifts, necessitating forward-thinking approaches to maintain competitive advantage and meet evolving healthcare needs.

KEY MARKET STATISTICS
Base Year [2023] USD 579.32 million
Estimated Year [2024] USD 620.10 million
Forecast Year [2030] USD 995.77 million
CAGR (%) 8.04%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hemostasis Diagnostics Market

The Hemostasis Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in incidences of hemostasis disorders worlwide
    • Inclination toward point-of-care testing solutions
    • Growing awareness of hemostasis disorders and emphasis on early diagnosis
  • Market Restraints
    • High cost of diagnosis and incidences of product recall
  • Market Opportunities
    • Utilization of personalized medicine approach to deliver tailored treatments
    • Advancements in diagnostic methods for hemostasis
  • Market Challenges
    • Complex testing methods for hemostasis diagnosis

Porter's Five Forces: A Strategic Tool for Navigating the Hemostasis Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hemostasis Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hemostasis Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hemostasis Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hemostasis Diagnostics Market

A detailed market share analysis in the Hemostasis Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hemostasis Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hemostasis Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hemostasis Diagnostics Market

A strategic analysis of the Hemostasis Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hemostasis Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ARUP Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, DiaPharma Group, Inc., F. Hoffmann-La Roche Ltd., Grifols, S.A., Haemonetics Corporation, Helena Laboratories Corporation, HemoSonics, LLC, HORIBA Group, Laboratory Corporation of America Holdings, Medtronic PLC, Merck & Co., Inc., Randox Laboratories Ltd., Siemens AG, Stago Group, Sysmex America, Inc., Sysmex Europe SE, Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, Thermo Fisher Scientific Inc., and Werfen, S.A..

Market Segmentation & Coverage

This research report categorizes the Hemostasis Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Consumables, Laboratory Analyzers, and Point-of-Care Testing Systems.
  • Based on Test Type, market is studied across Activated Clotting Time, Activated Partial Thromboplastin Time, D Dimer Test, Fibrinogen Test, Platelet Aggregation Test, and Prothrombin Time (PT) Test.
  • Based on End Use, market is studied across Home Care Setting, Hospitals/Clinics, and Independent Diagnostic Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in incidences of hemostasis disorders worlwide
      • 5.1.1.2. Inclination toward point-of-care testing solutions
      • 5.1.1.3. Growing awareness of hemostasis disorders and emphasis on early diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of diagnosis and incidences of product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Utilization of personalized medicine approach to deliver tailored treatments
      • 5.1.3.2. Advancements in diagnostic methods for hemostasis
    • 5.1.4. Challenges
      • 5.1.4.1. Complex testing methods for hemostasis diagnosis
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hemostasis Diagnostics Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Laboratory Analyzers
  • 6.4. Point-of-Care Testing Systems

7. Hemostasis Diagnostics Market, by Test Type

  • 7.1. Introduction
  • 7.2. Activated Clotting Time
  • 7.3. Activated Partial Thromboplastin Time
  • 7.4. D Dimer Test
  • 7.5. Fibrinogen Test
  • 7.6. Platelet Aggregation Test
  • 7.7. Prothrombin Time (PT) Test

8. Hemostasis Diagnostics Market, by End Use

  • 8.1. Introduction
  • 8.2. Home Care Setting
  • 8.3. Hospitals/Clinics
  • 8.4. Independent Diagnostic Laboratories

9. Americas Hemostasis Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hemostasis Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hemostasis Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. ARUP Laboratories
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. Danaher Corporation
  • 7. DiaPharma Group, Inc.
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Grifols, S.A.
  • 10. Haemonetics Corporation
  • 11. Helena Laboratories Corporation
  • 12. HemoSonics, LLC
  • 13. HORIBA Group
  • 14. Laboratory Corporation of America Holdings
  • 15. Medtronic PLC
  • 16. Merck & Co., Inc.
  • 17. Randox Laboratories Ltd.
  • 18. Siemens AG
  • 19. Stago Group
  • 20. Sysmex America, Inc.
  • 21. Sysmex Europe SE
  • 22. Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH
  • 23. Thermo Fisher Scientific Inc.
  • 24. Werfen, S.A.

LIST OF FIGURES

  • FIGURE 1. HEMOSTASIS DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HEMOSTASIS DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HEMOSTASIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HEMOSTASIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEMOSTASIS DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEMOSTASIS DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY LABORATORY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY ACTIVATED CLOTTING TIME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY D DIMER TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY FIBRINOGEN TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PLATELET AGGREGATION TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PROTHROMBIN TIME (PT) TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS/CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY INDEPENDENT DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 149. HEMOSTASIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. HEMOSTASIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023